BURWIG SUSAN E

EVP Susan Burwig sells 20,000 MEDP shares for $12.2M; reduces stake 42.1%, holds 27,500 post-sale

Susan Burwig, Executive Vice President of Operations, sold 20,000 shares of Medpace Holdings for $12,183,000.00 on 2025-11-24, reducing her position by 42.1% to 27,500 shares remaining. The sale occurred at $609.15, near the 52-week high of $618.49, suggesting opportunistic execution into strength. At Medpace specifically, Burwig has executed 5 prior trades with mixed outcomes: her most recent measurable result (2025-07-28) showed a +34.4% 90-day return after selling, but a 2024-06-05 sale produced a -12.8% 90-day return, indicating her timing at this ticker has been inconsistent. The broader stock has rallied +28.3% over 90 days and +1.7% over 30 days, and fundamentals remain solid with +11.8% annual revenue growth and net income of $111,135,000.00 on $659,903,000.00 quarterly revenue, though valuation has compressed at a P/E of 39.47.

Medpace EVP Burwig sells 18,000 MEDP shares at $605.00 for $10.9M, reducing stake 27.5% to 47.5K shares.

Susan E. Burwig, Executive Vice President of Operations, sold 18,000 shares at $605.00 on 2025-11-11, a substantial 27.5% reduction in her holdings. The transaction price of $605.00 is 1.3% below the 52-week high of $605.20, occurring as the stock is up 13.3% over 30 days and 30.3% over 90 days. Her cross-ticker track record shows mixed timing on sales: an average 30-day return of +1.1% and 90-day return of +22.3%, with a well-timed rate of 25.00%, indicating her prior sales were generally poorly positioned. At MEDP specifically, her same-ticker history reveals 1 of 3 prior measurable sales were well-timed (negative 90-day outcome); most notably, her 2025-07-28 sale preceded a 34.4% gain at the 90-day mark. The company fundamentals remain solid with $659.9M in latest quarterly revenue and net income of $111.1M against a P/E of 38.88, suggesting the stock remains richly valued. The sale does not follow an obvious market weakness signal but occurs after sustained upward momentum.

Exec. VP Susan Burwig sold 2,000 shares of MEDP at $605.01 on 2025-10-27, retaining 65,500 shares; sale near 52-week high.

Susan Burwig, Exec. VP of Operations, sold 2,000 shares (2.0K shares) at $605.01, a price within 3.4% of the 52-week high of $605.20, while retaining a substantial position of 65,500 shares (65.5K shares). Across her cross-ticker track record, her prior sells have averaged a 90-day return of +22.3% with a 25.00% well-timed rate, though her same-ticker history at MEDP shows only 1 of 4 prior measurable 90-day outcomes were well-timed (negative post-sale returns). The stock has gained 16.7% over 30 days and 36.8% over 90 days since the transaction, indicating the sale occurred within a strong uptrend. With MEDP trading at a P/E of 38.03 and posting 11.8% annual revenue growth against a $16.5B market cap, the execution at near peak valuation may merit monitoring for context on broader insider sentiment at elevated price levels.

Exec. VP Burwig sells 10.0K MEDP shares at $480.00 for $4.8M; stock at 52-week high, up 13.2% in 30d, 64.2% in 90d

Susan E. Burwig, Exec. VP of Operations, sold 10,000 shares at $480.00, reducing her MEDP holdings from 67,500 to 57,500 shares (-14.8%). The sale occurred near the stock's 52-week high of $486.98, after the stock rallied 13.2% in the prior 30 days and 64.2% over 90 days. Burwig's cross-ticker track record shows 4 prior sells with only 33.33% well-timed at the 90-day mark (1 of 3 measurable outcomes), suggesting modest predictive accuracy. At the same ticker (MEDP), her prior 4 sells showed mixed outcomes: 1 of 3 prior sells that reached the 90-day mark were well-timed, with the most recent sale on 2025-07-28 showing +5.2% at 30 days. The company reports $603.3M in latest-quarter revenue with +11.8% annual growth and a P/E of 32.71, indicating a mature, growing business trading at a premium valuation. The sale's proximity to a 52-week high and 90-day peak mirrors a pattern of modest hit rates in her prior sales, providing limited directional signal on near-term stock trajectory.

MEDP insider VP sells 7,500 shares at $450.14; stock +44.2% in 30 days, up 45.2% in 90 days post-transaction

Susan E. Burwig, Exec. VP of Operations, sold 7,500 shares of Medpace Holdings on 2025-07-28 at $450.14, reducing her holdings by -11.5% to 57,500 shares. The sale was valued at $3,376,050.00. Since the transaction, MEDP has appreciated sharply—up +44.2% over 30 days and +45.2% over 90 days—a pattern that typically reflects poorly-timed exit decisions by the seller. Across her prior open-market transaction history at all tickers, Burwig's three prior sells yielded an average 90-day return of +18.3%, with a well-timed rate of 33.33%, indicating her sell timing has historically missed upside moves. At this specific ticker (MEDP), her prior three trades show a 33.3% well-timed rate at the 90-day mark, suggesting limited predictive consistency in her transaction timing at this company. The company's fundamentals remain solid (revenue $603.3M, net income $90.3M, annual growth +11.8%), and the stock remains within its 52-week range, now -6.2% from its 52-week high of $477.73.